N
CLDX icon

Natixis’s Celldex Therapeutics CLDX Stock Holding History

Natixis’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-232,188
Closed -$4.16M – 1054
2025
Q1 		$4.16M Buy
232,188
+216,388
+1,370% +$4.83M 0.02% 333
2024
Q4 		$399K Buy
+15,800
New +$429K ﹤0.01% 736
2024
Q3 		– Sell
-165,500
Closed -$6.13M – 985
2024
Q2 		$6.13M Sell
165,500
-48,400
-23% -$1.83M 0.04% 274
2024
Q1 		$8.98M Buy
+213,900
New +$8.78M 0.05% 249

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return